Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Regenxbio (RGNX) EBT Margin (2016 - 2025)

Historic EBT Margin for Regenxbio (RGNX) over the last 12 years, with Q3 2025 value amounting to 208.39%.

  • Regenxbio's EBT Margin rose 380100.0% to 208.39% in Q3 2025 from the same period last year, while for Sep 2025 it was 110.38%, marking a year-over-year increase of 1731000.0%. This contributed to the annual value of 272.54% for FY2024, which is 196100.0% up from last year.
  • As of Q3 2025, Regenxbio's EBT Margin stood at 208.39%, which was up 380100.0% from 331.91% recorded in Q2 2025.
  • In the past 5 years, Regenxbio's EBT Margin ranged from a high of 77.13% in Q4 2021 and a low of 405.63% during Q1 2024
  • Moreover, its 5-year median value for EBT Margin was 246.4% (2024), whereas its average is 239.05%.
  • Per our database at Business Quant, Regenxbio's EBT Margin tumbled by -2684800bps in 2022 and then surged by 4124300bps in 2025.
  • Regenxbio's EBT Margin (Quarter) stood at 77.13% in 2021, then plummeted by -348bps to 191.35% in 2022, then tumbled by -48bps to 283.8% in 2023, then rose by 15bps to 241.68% in 2024, then rose by 14bps to 208.39% in 2025.
  • Its EBT Margin was 208.39% in Q3 2025, compared to 331.91% in Q2 2025 and 6.81% in Q1 2025.